Moreover, GRP78 and PERK could be coprecipitated in the highly aggressive breast cancer cells, and their interaction was interrupted following BA treatment in a dose-dependent manner (Figure 4(f), Supplementary ). The gene discussed is HSPA5; the disease is breast carcinoma.